focus -WSS

focus

author：fashion 2025-08-12 05:30:45 - browse：79629

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： ARCH Venture Partners is raising $3 billion for a life sciences fund

WSS

Printout prescription drug information shouldn’t go digital

There's an unseen cost to disruptive road

Biden administration opens offers in Medicare drug price negotiations

The real point of Kenneth Smith’s execution by nitrogen gas

SAMSHA loosens regulations on methadone treatment centers

Vertigo drug brings hope for rare neuron disorder, Niemann

explore

focus

knowledge

Medicare details structure of new drug price negotiation program

High breast density mammograms need follow

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dana Farber says 6 studies to be retracted and 31 corrected

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Some dementia cases could be undiagnosed liver disease

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden administration opens offers in Medicare drug price negotiations

Virginia high school admissions case could be legal follow

Microsoft launches AI tool for clinical documentation through Epic

entertainment

Biden administration opens offers in Medicare drug price negotiations

Even great ERs can’t make up for American health disparities

Cognito secures funding to test medical device for Alzheimer's

Some dementia cases could be undiagnosed liver disease

Maisha Meds is a PBM, but don't call it that

Cognito secures funding to test medical device for Alzheimer's

focus

knowledge

focus

knowledge